Merck & Co Inc (NYSE:MRK) Lagevrio (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household…
CVRx Inc (NASDAQ:CVRX) announced the preliminary topline results of the BeAT-HF (Baroreflex Activation Therapy for Heart Failure) post-market randomized clinical trial.…
The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT.
No New Safety Signals Were Seen
Tumor tissues were analyzed to determine potential predictors of treatment response to MN-166 (ibudilast) and temozolomide (TMZ) combination treatment.
Pre-treatment tumor tissues were obtained from the resected
The Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. to outright purchase intellectual property, including a pending patent, associated with a portfolio of novel gene